Pacira BioSciences Inc Dossier - Source-backed chat

Pacira BioSciences Inc

PCRXNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.51

Intrinsic Value $28.16median of 6 methods · middle span $18-$32based on filings through 30 Jun 2026

Market Price $25.01Price as of 1 Oct 2026

Near fair valueIntrinsic value is 13% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $984.1M

Enterprise Value $1.1B

Shares Outstanding 39.8M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pacira BioSciences is executing its '5x30' strategic plan to transition into an innovative biopharmaceutical leader in musculoskeletal pain. While Q1 2026 results demonstrated solid commercial momentum with a 5% revenue increase to $177.4 million, near-term profitability remains constrained by rising R&D investments and margin pressures. The company successfully defended its board slate against activist DOMA Perpetual Capital Management at the June 2026 AGM, but governance overhang and generic bupivacaine liposome entry risks in 2030 warrant a cautious near-term outlook. The stock is currently valued fairly as the market awaits key clinical readouts for PCRX-201 and ZILRETTA later in 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.00

Mean target$30.00

High · most bullish analyst$38.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects slower-than-expected NOPAIN Act conversion, pricing pressure from payers, and rising operational expenses that compress margins. Pipeline setbacks, such as unfavorable safety or efficacy signals in the PCRX-201 ASCEND trial, or renewed legal challenges to EXPAREL's patent estate, could lead to multiple contraction.

Base CaseCentral scenario

The base case assumes steady commercial execution of the core portfolio, with EXPAREL maintaining its dominant market share supported by the NOPAIN Act reimbursement tailwinds. ZILRETTA and iovera° continue to grow incrementally through targeted co-promotion partnerships. Operating margins stabilize as the company balances pipeline investments with cost controls, achieving its reiterated full-year 2026 revenue guidance of $745 million to $770 million.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial foundation anchored by EXPAREL, which continues to dominate the non-opioid postsurgical pain market.
Favorable regulatory tailwinds from the NOPAIN Act, providing direct Medicare reimbursement incentives in outpatient settings.
Strategic commercial collaborations, such as the co-promotion agreement with Johnson & Jonson MedTech for ZILRETTA.
Robust balance sheet with $202.2 million in cash and investments to support pipeline development and share buybacks.

Key Investment Risks

High concentration risk with EXPAREL contributing approximately 80% of total revenues.
Long-term generic threat following a patent settlement that permits volume-limited generic entry starting in early 2030.
Near-term margin compression driven by elevated R&D expenses for late-stage clinical programs.
Ongoing governance and strategic execution scrutiny following the proxy contest with DOMA Perpetual.

Thesis Invalidation Triggers

Failure of EXPAREL to meet the lower bound of its full-year 2026 sales guidance ($600 million).
Negative or inconclusive topline results from the PCRX-201 Phase 2 ASCEND study.
A significant slowdown in NOPAIN Act-driven volume growth during the second half of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.